[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-hemorrhagic-hydrocephalus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-hemorrhagic-hydrocephalus":77},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100624688","advanced-mri-in-ivh-100624688",false,"NCT07412886","Advanced MRI in IVH","Advanced MRI in Preterm Intraventricular Haemorrhage: Uncovering Mechanisms of Disease and Novel Treatments","Neonates with PHVD who have been referred to and\u002For have undergone neurosurgical treatment at Great Ormond Street Hospital (GOSH) and Alder Hey Children's Hospital (AHCH) (15 neonates in each) will be eligible for inclusion.\n\nThe majority of neonates will be recruited to the ENLIVEN-UK randomised clinical trial and involvement will not preclude recruitment to this study.\n\nThe only exclusion criteria will be lack of informed consent from the parent\u002Fcarer.","ALL",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"NA","55,000 babies are born prematurely in the UK annually. Bleeding in the fluid spaces of the brain (ventricles) is common after prematurity; in England around 450 babies suffer from severe bleeds every year. This is the most important cause of neurological disability after prematurity. Bleeding occurs in the first week of life when the brain is developing rapidly and is most vulnerable to injury. The blood and its breakdown products in the brain fluid (cerebrospinal fluid, CSF) are toxic to the developing brain and cause scarring that blocks the flow and absorption of CSF. In about half these babies, this causes fluid build-up, or post-haemorrhagic ventricular dilatation (PHVD).\n\nCurrent standard treatment of PHVD only drains CSF to reduce pressure inside the brain. Following early results and a successful pilot study at GOSH, we developed an NIHR-funded randomised national trial to analyse the impact of an operation to wash out blood inside the brain using a small endoscope. We will compare standard treatment (fluid drainage alone) with washout plus drainage of fluid.\n\nPremature babies typically undergo an MRI scan of the brain at their expected birth time to assess their brain injury, predict the severity of their disability and see what early rehabilitation and treatment they need. In this study we will use new MRI techniques during this scan at GOSH and Alder Hey Hospital to better understand the extent of brain injury in relation to brain structure, function and brain fluid flow. We want to see whether these will show the impact of the washout procedure, tell us about how washout works, and improve prediction of the child's disability and early treatment needs. If successful, we will apply for further funding to extend these techniques to the other centres in the UK and maximise their benefit within the NHS.",[25,26],"Intraventricular Hemorrhage Neonatal","Post-hemorrhagic Hydrocephalus",[28,29,30,31],"intraventricular hemorrhage","post-hemorrhagic ventricular dilatation","magnetic resonance imaging","cognitive development","NOT_YET_RECRUITING","2026-02-09",{"date":35,"type":36},"2026-02-17","ACTUAL",{"date":38,"type":19},"2026-02-16",{"date":40,"type":19},"2027-05-01",{"name":42,"class":43},"Great Ormond Street Hospital for Children NHS Foundation Trust","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":20,"phases":56,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100559414","phase-2-the-safety-and-efficacy-of-rapamycin-on-communicating-hydrocephalus-secondary-to-intraventricular-hemorrhage-100559414","NCT06563817","The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular Hemorrhage","A Prospective, Multi-center, Open-label Study to Observe the Efficacy and Safety of Rapamycin in the Treatment of Communicating Hydrocephalus Secondary to Intraventricular Hemorrhage","Saturn","Inclusion Criteria:\n\n1. Patients with ventricular dilatation due to intraventricular hemorrhage who clinically present with any one or more of new gait disturbances, cognitive deficits, and urinary incontinence after remission of intraventricular hemorrhage symptoms, and whose brain imaging shows an Evans index (EI) of ≥0.3\n2. Age ≥ 18 years and ≤ 70 years\n3. Signed informed consent form\n\nExclusion Criteria:\n\n1. Participation in another medical trial\n2. Have other disease that may affect the patient's symptoms (including gait disturbance, cognitive impairment, urinary incontinence)\n3. Allergy to the investigational drug\n4. Reduced liver function (increased INR or alanine transaminase concentrations in plasma elevated more than 1.5 times reference values)\n5. Reduced kidney function with GFR \\\u003C 50\n6. Concomitant treatment with strong CYP3A4\u002F5 inducers or inhibitors, such as diltiazem, ketoconazole, or rifampicin.\n7. Active or uncontrolled chronic infection\n8. Women who are pregnant or breastfeeding\n9. Patients who are bedridden or require urinary catheters for extended periods of time.","18 Years","70 Years",{"count":55,"type":19},53,[57],"PHASE2","This prospective, multicenter, open-label clinical trial is designed to evaluate the safety and efficacy of rapamycin in the treatment of communicating hydrocephalus secondary to intraventricular hemorrhage. Additionally, the underlying pathogenic mechanisms associated with this particular type of hydrocephalus will be investigated in greater depth, and populations that may benefit from rapamycin therapy will be identified.",[60,61,62,63],"Communicating Hydrocephalus","Cerebral Intraventricular Hemorrhage","Secondary Normal Pressure Hydrocephalus","Post Hemorrhagic Hydrocephalus",[60,61,65,62,63],"Rapamycin","RECRUITING","2024-08-18",{"date":69,"type":36},"2024-08-21",{"date":71,"type":19},"2024-08",{"date":73,"type":19},"2025-07",{"name":75,"class":43},"Beijing Tiantan Hospital",1,"Post-Hemorrhagic Hydrocephalus"]